INTRODUCTION
Adoptive immunotherapy using chimeric antigen receptor (CAR)-engineered autologous T-cells has achieved unprecedented efficacy in the treatment of patients with refractory B-cell malignancy. [1] [2] [3] In this context, the CD19 molecule provides a target par excellence, since toxicity arising from the depletion of healthy B-cells can be mitigated with immunoglobulin replacement therapy. However, solid tumors present several additional hurdles to the development of effective CAR T-cell immunotherapy. Unlike B-cell malignancy, lineage-restricted molecules are generally unsuitable for targeting owing to their expression at high levels by one or more critical organs. Broadly speaking, two alternative approaches warrant consideration. First, tumorspecific mutations (eg epidermal growth factor receptor variant III) provide attractive opportunities for immunotherapy of selected cancers. 4, 5 However, target expression is sporadic, subject to intra-tumoral heterogeneity and downregulation upon disease relapse. 6, 7 Alternatively, targeting may be directed against molecules that are over-expressed on transformed cells relative to healthy tissue, such as ErbB2. While initial clinical testing resulted in lethal toxicity, 8 more recent evaluation of this strategy has demonstrated that an efficacy signal can be achieved safely using CAR + T-cells. 9 This provides a strong rationale for the identification and validation of additional targets that are not absolutely tumor specific, but which are strongly upregulated on transformed cells and contribute to disease pathogenesis.
One such candidate is the epithelial-specific integrin, αvβ6. Cell surface expression requires pairing of the monogamous β6 chain with the more promiscuous αv partner. 10 αvβ6 is commonly over-expressed in solid tumors derived from pancreas, head and neck, skin, lung, esophagus, stomach, colon, breast, uterine cervix and fallopian tube/ovary and is generally associated with worsened prognosis. [11] [12] [13] [14] [15] [16] [17] In keeping with this, αvβ6 activates pro-transforming growth factor-β and promotes epithelial to mesenchymal transition, cellular migration and matrix metalloproteinase activity. [18] [19] [20] [21] By contrast, this integrin is minimally expressed in adult tissue, except during wound healing. 17, 22 In light of these attributes, αvβ6 has attracted significant interest as a target for antibody-based imaging and treatment of many cancer types. 14, 23, 24 Infection of several species by the foot and mouth disease virus (FMDV) is mediated by the ability of the viral protein 1 coat protein to bind to a number of integrins, including αvβ6. 25 A derived 20mer peptide (A20FMDV2) has been characterized as an effective antagonist of αvβ6 26 and has been used to image αvβ6-positive tumors. 27 We hypothesized that this 20mer would represent a suitable moiety to engineer an αvβ6-targeted CAR since it contains two overlapping αvβ6-binding motifs (RGD and DLXXL) and binds with >1000-fold greater specificity to this integrin than to other family members, such as αvβ3, αvβ5 and α5β1. 13, 28 Using A20FMDV2 as a targeting moiety, we describe for the first time the development of an αvβ6-specific CAR that elicits potent therapeutic activity against diverse solid tumor types, without significant toxicity. 
Comparison of in vitro anti-tumor activity of candidate αvβ6-targeted CARs
To engineer candidate αvβ6 CARs, the A20FMDV2 peptide (A20) 26 or a phage display-derived 12mer peptide (B12) 29 were fused to a human CD28 spacer (from amino acid 114, in which MYPPPY was replaced by a 9e10 myc tag), followed by a CD28+ transmembrane/endodomain and CD3ζ endodomain. CARs were named A20-28z and B12-28z and contain two or one αvβ6
binding sites respectively (Figure 1a-b) . A scrambled derivative of A20 (C20, in which RGDL is replaced by AAAA; Figure 1a ) or truncated CD28 endodomain (Figure 1c ) were used to create control CARs (named C20-28z and A20-Tr respectively) 30 In light of these findings, A20-28z was advanced and B12-28z was discarded. Specificity of integrin targeting was evaluated in cytotoxicity assays using A375 cells that naturally express several RGD-binding integrins, including αvβ3, αvβ5, αvβ8 and α5β1 but not αvβ6 (Figures 1f   and 1g) . 24 Comparison was made with cytotoxicity against a β6 + A375 derivative (Figure 1g) . In an extended cytotoxicity assay that lasted 1 -7 days, A20-28z + T-cells killed β6 + but not control A375 cells (Figure 1h) , accompanied by β6-dependent IFN-γ release (Figure 1i ). As expected, neither A20-Tr + nor C20-28z + T-cells demonstrated cytotoxic activity in these assays. In order to further characterise the specificity of the A20 peptide, its binding capacity for other integrins was also assessed. Addition of increasing amounts of biotinylated A20 peptide led to proportionately greater binding to both A375 β6 cells (Figure 1j ) and to recombinant αvβ6 (Figure 1k ). By contrast, the A20 peptide did not exhibit any detectable binding to A375 puro cells or to other RGD-binding integrins (Figure 1j-k) .
Expansion of αvβ6 re-targeted T-cells using interleukin-4
To preferentially expand αvβ6-re-targeted T-cells ex vivo, CARs were stoichiometrically co- Figure S8c) .
Human CAR T-cells recognize mouse αvβ6 but cause mild, transient and fully reversible toxicity at supra-therapeutic dose levels
The FMDV 20mer also binds mouse αvβ6 with high affinity. 28 To test if human A20-28z + Tcells engage the mouse αvβ6 ortholog, co-cultivation experiments were performed using 4T1 We have previously shown that CAR T-cells delivered using the i.p. route remain largely in the peritoneal cavity. 34 Nonetheless, they can trigger severe macrophage-dependent cytokine release syndrome (CRS), particularly in the presence of advanced tumor burden. 33 Such toxicity was not seen in the tumor xenograft models presented above. However, i.p. delivery may not permit human CAR T-cells to access all sites where αvβ6 is naturally expressed in mice, notably gastrointestinal epithelium. 28 Consequently, we performed a study in which bolus doses of CAR 
DISCUSSION
Aberrant expression of the epithelial-specific integrin αvβ6 is prevalent in several cancers. [11] [12] [13] [14] [15] [16] 18 The pro-invasive effect of αvβ6 is most graphically illustrated by its predominant expression at the infiltrating margin of the tumor mass. 11 By contrast, expression of this integrin is scarcely detectable in healthy human tissues, 17, 22 rendering it a highly attractive candidate for immunotherapeutic targeting. Here, we show for the first time that T cells engineered to express an αvβ6-specific CAR mediate therapeutic activity against a broad range of solid tumor types, both in vitro and in vivo.
To engineer candidate αvβ6-targeted CAR T-cells, two integrin-binding peptides were coupled to matched hinge, transmembrane and CD28+CD3 endodomain modules. The FMDV-derived A20 peptide has been extensively characterised for its ability to bind specifically to αvβ6 but not to other αv-based heterodimeric integrins. We found that T-cells engineered to express an A20-derived CAR (A20-28z) killed tumor cell types of diverse origin, accompanied by cytokine release. Importantly, the magnitude of these effector activities correlated closely with cell surface expression of αvβ6 integrin, meaning that target cells with very low levels of αvβ6 (e.g. Panc-1, CAL51) were ignored. We also evaluated an alternative second generation CAR that was targeted using a 12mer peptide, isolated by phage display. 29 The B12 peptide had been used to engineer a first-generation CAR to which some in vitro anti-tumor activity had been attributed. 35 However, this was demonstrated using a re-stimulated CD8 + T-cell line (isolated following hygromycin selection) and two derived CD8 + T-cell clones. When we re-evaluated this peptide in the context of a second generation CAR which was expressed in unselected primary human T-cells, negligible anti-tumor activity was observed. Given that the B12 peptide is shorter, it is possible that cognate epitope is not accessible by this very short peptide. Consequently, A20-28z alone was advanced for further study.
In vivo efficacy of A20-28z CAR T-cells was demonstrated in four established xenograft models, representative of PDAC, breast and ovarian cancer. Using a dual BLI imaging strategy, we demonstrated that αvβ6 re-targeted A20-28z + CAR T-cells declined progressively in the days following delivery. This may account for the delayed tumor relapse observed, providing a rationale for the exploration of repeated T-cell administration in future studies.
32
Prior to adoptive transfer, genetically engineered T-cells were enriched during ex vivo expansion since the CAR was co-expressed with 4αβ, a chimeric cytokine receptor that allows selective IL-4-mediated proliferation of CAR T-cells. 31 This approach is now in use in a Phase 1 clinical trial in patients with locally advanced or recurrent head and neck cancer. In that setting, a broadly reactive ErbB-specific CAR is co-expressed with 4αβ, allowing IL-4-mediated expansion of cell products prior to intra-tumoral delivery. 37 This approach obviates the need for leukapheresis since over 2 billion CAR + T-cells can reliably be expanded/ enriched within 2 weeks from 120mL blood, even from patients with advanced malignancy and profound lymphopenia. To date, eight CAR T-cell batches have been produced in this ongoing trial that have exceeded these specifications, without any batch failures (data not shown).
In our study, we used the 4 system as a means of in vitro expansion. However, IL-4 is also produced in vivo in humans, and may be overproduced in the tumor microenvironment. As discussed previously, 31 this could theoretically benefit anti-tumor activity but might also enhance toxicity of this approach. In our study, we found that provision of exogenous IL-4 cytokine support did not improve anti-tumor activity of CAR T-cells or their long-term survival. This may have been because of the very short half-life of IL-4 in vivo. Moreover, combination IL-4 and CAR T-cell treatment did not increase toxicity, although human IL-4 is not active in the mouse.
Meaningful safety testing of human A20-28z + CAR T-cells could be undertaken in SCID Beige mice for three reasons. First, the A20 FMDV targeting moiety can bind to mouse αvβ6 integrin with comparable affinity to the human ortholog. 28 As a result, human A20-28z + CAR T-cells also recognize mouse tumor cells that express this integrin. Second, we have previously shown that i.p. delivery of human ErbB re-targeted CAR T-cells can elicit severe CRS in SCID Beige mice, in a manner that is accentuated by high tumor burden. In that setting, macrophage activation (a functionality that is preserved in SCID Beige mice) accompanied by IL-6 release play a pivotal role, 33 recapitulating the key role of these intermediates in human CRS. 38 Third, expression of αvβ6 in mice is proportionately greater than in man, most notably in the gastrointestinal tract. 28 In keeping with this, laboratory mice are highly susceptible to FMDV, 39 unlike man in which this viral illness is an extraordinarily unusual zoonosis. 40 Reassuringly however, minimal toxicity accompanied tumor regression in all four xenograft models following treatment with αvβ6-targeted A20-28z CAR T-cells. Administration of very large doses using the i.v. route did result in reversible toxicity which was dependent upon an intact αvβ6-targeted CAR.
Taken together, these data justify the evaluation of αvβ6-targeted CAR T-cell immunotherapy for tumors in which aberrant expression of this integrin is present. We are currently developing a strategy for Phase 1 evaluation of this approach in patients with otherwise untreatable αvβ6-expressing malignancy.
MATERIALS AND METHODS

Retroviral constructs.
To enable detection of CARs, a myc epitope-tagged framework was engineered (Figure 1b-d) . A codon-optimized cDNA was synthesized to encode for human CD28 (amino acids 114 to 200) in which B7-binding residues 117-122 (MYPPPY) were substituted with residues 410-419 of human c-myc (EQKLISEEDL) (Mr Gene, Regensburg, Germany). The sequence was flanked by 5' Not1 and 3' Apa1 restriction sites and was substituted for the corresponding fragment in SFG T1E28z, (encodes a broadly ErbB reactive CAR with a CD28+CD3 endodomain). 41 The resultant myc epitope-tagged CAR (Tm28z) exhibited comparable function to T1E28z (data not shown). Next, codon-optimized cDNAs were synthesized in which two candidate αvβ6-binding peptide sequences were fused to signal peptides selected for correct cleavage site using SignalP 3.0 server [42] (Genscript, Piscataway, NJ; Figure 1a) . The VP1-derived A20FMDV2 20mer peptide was placed downstream of a CD124 signal peptide (A20). 43 A control (αvβ6 non-binding) peptide was generated in which the RGDL motif within A20FMDV2 was substituted with AAAA (C20). To engineer an alternative CAR targeting moiety, a previously described αvβ6-binding 12mer peptide (isolated by phage display). 29, 35 was placed downstream of a human CD3 signal peptide (B12) (Figure 1a) . All cDNAs were substituted for the smaller Nco1/Not1 fragment within SFG Tm28z. The resultant CARs were named A20-28z, C20-28z and B12-28z (Figure 1b ). An endodomain truncated control CAR (A20-Tr) was also engineered in which the Not1/ Xho1 fragment within A20-28z
was substituted with a smaller synthetic cDNA (Genscript) encoding CD28 residues 114-182 (in which MYPPPY was replaced by the myc epitope tag; Figure 1c) . Kettering Cancer Center, NY) and were propagated as described. 45 All tumor cell lines were validated by short tandem repeat DNA profiling and experiments were performed within 30 passages of receipt.
Flow cytometry analysis. Expression of αvβ6 was detected using the 6.3G9 antibody, 46 followed by goat anti-mouse Ig-PE (Dako, Ely, UK) and was expressed as percentage positivity and/ or geometric mean fluorescence intensity. Cells stained with secondary antibody only served as a negative control. Expression of CARs was detected using supernatant derived from the 9e10 hybridoma (ECACC), which binds to residues 410-419 of human c-myc, followed by goat anti-mouse Ig-PE. Untransduced T-cells acted as a negative control. CD8 expression was detected using PE-conjugated PNIM0452 (Immunotech, Marseille, France). Phenotypic analysis of T-cells was performed using anti-CCR7 (R&D systems FAB197F) and CD45RO (Biolegend 304210) antibodies. In some assays, populations were gated on CAR + cells detected using an antibody against CD124 (BD Pharmingen, 552178). To assess integrin specificity of the A20 peptide, biotinylated peptide (Genscript, Hong Kong Ltd) was diluted in PBS supplemented with The arrow indicates the day of treatment with CAR T-cells.
